References
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
- Psoriasis.org [Internet]. Psoriasis statistics. Portland, OR: National Psoriasis Foundation/USA; c1996–2020 [updated 2020 Oct 8; cited 2020 Dec 9]. Available from: https://www.psoriasis.org/psoriasis-statistics
- Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19.
- Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019;6(1):23–32.
- Singh J, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32.
- Drugs.com [Internet]. Drugs.com; c2000–2020 [cited 2020 Dec 9]. Available from: Drugs.com
- Gottlieb A, Gratacos J, Dikranian A, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int. 2019;39(1):121–130.
- Harrold LR, Stolshek BS, Rebello S, et al. Rebound in measures of disease activity and symptoms in Corrona Registry patients with psoriatic arthritis who discontinue tumor necrosis factor inhibitor therapy after achieving low disease activity. J Rheumatol. 2018;45(1):78–82.
- Belinchón I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367.
- Jevtić T, Bukumiric Z, Jankovic SM. Effects of treatment adherence on clinical and economic outcomes in patients with psoriasis. Med Glas. 2013;10:106–112.
- Oelke KR, Chambenoit O, Majjhoo AQ, et al. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8(8):607–621.
- Walsh JA, Adejoro O, Chastek B, et al. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623–631.
- Walsh JA, Cai Q, Lin I, et al. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin. 2020;36(7):1245–1252.
- Perrone V, Giacomini E, Sangiorgi D, et al. Treatment pattern analysis and health-care resource consumption on patients with psoriatic arthritis or ankylosing spondylitis treated with biological drugs in a northern Italian region. Ther Clin Risk Manag. 2020;16:509–521.
- Humira (adalimumab) [Package insert] [Internet]. North Chicago, IL: AbbVie Inc; [revised 2020 Mar; cited 2020 Dec 9]. Available from: https://www.rxabbvie.com/pdf/humira.pdf?_ga=2.149213686.1370138459.1588187822-334049247.1588187822
- Cimzia (certolizumab pegol) [Package insert] [Internet]. Smyrna, GA: UCB, Inc; [revised 2019 Sep; cited 2020 Dec 9]. Available from: https://www.ucb.com/_up/ucb_com_products/documents/Cimzia_09_11_2019_en.pdf
- Enbrel (etanercept) [Package insert] [Internet]. Thousand Oaks, CA: Amgen Inc. [revised 2020 Mar; cited 2020 Dec 9]. Available from: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/enbrel/enbrel_pi.pdf
- Tremfya (guselkumab) [Package insert] [Internet]. Horsham, PA: Janssen Biotech, Inc; [revised 2019 Nov; cited 2020 Dec 9]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf
- Taltz (ixekizumab) [Package insert] [Internet]. Indianapolis, IN: Eli Lilly and Company; [revised 2020 Mar; cited 2020 Dec 9]. Available from: http://uspl.lilly.com/taltz/taltz.html#pi
- Cosentyx (secukinumab) [Package insert] [Internet]. East Hanover, NJ: Novartis Pharmaceutical Corporation; [revised 2020 Jan; cited 2020 Dec 9]. Available from: https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
- Stelara (ustekinumab) [Package insert] [Internet]. Horsham, PA: Janssen Biotech, Inc; [revised 2020 Mar; cited 2020 Dec 9]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
- Zhang M, Carter C, Olson WH, et al. Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol. 2017;16(3):220–226.
- Gendelman O, Weitzman D, Rosenberg V, et al. Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. Br J Clin Pharmacol. 2018;84(4):786–795.
- Wang Q, Luo Y, Lv C, et al. Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: a web-based survey. Patient Prefer Adherence. 2020;14:1403–1409.